Johnson & Johnson (NYSE:JNJ) Holdings Decreased by Logan Capital Management Inc.

Logan Capital Management Inc. reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 1.2% in the 3rd quarter, Holdings Channel reports. The fund owned 47,122 shares of the company’s stock after selling 576 shares during the period. Logan Capital Management Inc.’s holdings in Johnson & Johnson were worth $7,637,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Innealta Capital LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth approximately $27,000. Highline Wealth Partners LLC purchased a new stake in Johnson & Johnson in the 3rd quarter worth approximately $31,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of Johnson & Johnson during the 3rd quarter valued at $35,000. Mowery & Schoenfeld Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after acquiring an additional 91 shares in the last quarter. Finally, Activest Wealth Management acquired a new position in shares of Johnson & Johnson in the third quarter worth $40,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have commented on JNJ shares. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Morgan Stanley increased their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Bank of America reiterated a “neutral” rating and issued a $166.00 target price on shares of Johnson & Johnson in a research note on Tuesday. Guggenheim increased their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada lifted their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $174.73.

Johnson & Johnson Stock Performance

JNJ traded down $0.89 during midday trading on Friday, reaching $145.35. The company’s stock had a trading volume of 727,899 shares, compared to its average volume of 7,090,866. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The stock has a market cap of $349.95 billion, a P/E ratio of 21.16, a PEG ratio of 2.52 and a beta of 0.51. The company has a fifty day simple moving average of $157.01 and a 200 day simple moving average of $156.28. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. Johnson & Johnson’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.66 earnings per share. Research analysts expect that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th were paid a dividend of $1.24 per share. The ex-dividend date was Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.41%. Johnson & Johnson’s dividend payout ratio is 71.78%.

Insider Buying and Selling at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.